Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 6/20 | 0.36 |
| ▸ | GSK3B | P49841 | 5/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.36 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | KCNB1 | Q14721 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | IL17A | Q16552 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19002703 | 0.84 | LOXL2 (0.53) | LOXLOXL2ACACBENPP2FFAR1 | |
| SCHEMBL20665576 | 0.83 | GRM5 (0.34) | — | |
| SCHEMBL26540427 | 0.82 | LOX (0.54) | LOXLOXL2ACACBFFAR1CDK2 | |
| SCHEMBL19002701 | 0.81 | LOXL2 (0.49) | LOXLOXL2ACACBENPP2FFAR1 | |
| SCHEMBL21900624 | 0.79 | ACACB (0.43) | ACACBENPP2 | |
| SCHEMBL4018107 | 0.74 | LOXL2 (0.59) | LOXLOXL2ACACBENPP2FFAR1 | |
| SCHEMBL2092744 | 0.73 | LOXL2 (0.67) | LOXLOXL2ACACBENPP2FFAR1 | |
| SCHEMBL14935708 | 0.73 | CA1 (0.50) | FFAR1 | |
| SCHEMBL14945752 | 0.72 | RAB9A (0.47) | — | |
| SCHEMBL18082590 | 0.71 | LOX (0.51) | LOXLOXL2ACACBFFAR1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | LOX 2465/4885LOXL2 1691/4885ACACB 2691/4885 |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | LOX 2465/4885LOXL2 1691/4885ACACB 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.